Go Pro
NASDAQ:BBLG

Bone Biologics Q1 2026 Earnings Report

Bone Biologics logo
$0.62 0.00 (-0.03%)
As of 08/28/2026 04:00 PM Eastern

Bone Biologics EPS Results

Actual EPS
-$0.43
Consensus EPS
-$0.43
Beat/Miss
Met Expectations
One Year Ago EPS
N/A

Bone Biologics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Bone Biologics Announcement Details

Quarter
Q1 2026
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Bone Biologics' next earnings date is estimated for Friday, November 13, 2026, based on past reporting schedules.

Conference Call Resources

Bone Biologics Earnings Headlines

Bone Biologics Corp. (NASDAQ:BBLG) Sees Large Growth in Short Interest
Zacks Research Cuts Earnings Estimates for Bone Biologics
The cat is out the bag
Almost 80,000 tech jobs vanished in the first three months of 2026. Meta cut 14,000 roles, Microsoft offered separation packages to 8,500 workers, and Oracle is reportedly eliminating up to 30,000 positions. Goldman Sachs estimates 12,400 Americans are being financially displaced every single day. Analyst Porter Stansberry says the real driver runs deeper than AI - and two Nobel Prize winners have issued the same warning. He calls it the Final Displacement, and he's releasing a full investigation with specific companies to buy and sell before the next wave hits.tc pixel
BBLG Efficiency Improves as Crucial Trials Advance
See More Bone Biologics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Bone Biologics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Bone Biologics and other key companies, straight to your email.

About Bone Biologics

Bone Biologics (NASDAQ:BBLG), Inc. (NASDAQ: BBLG) is a clinical-stage biotechnology company focused on the development of cell-based therapies for skeletal repair and regeneration. The company’s research efforts center on both allogeneic and autologous mesenchymal cell platforms designed to enhance bone healing in patients with orthopedic injuries and degenerative bone conditions. Its approach aims to provide alternatives to traditional grafting procedures by harnessing the regenerative potential of specialized stem cells.

Leveraging proprietary cell expansion and delivery technologies, Bone Biologics is advancing a pipeline of investigational therapies targeting indications such as spinal fusion, long-bone non-union and maxillofacial defects. Early-stage clinical studies and preclinical investigations are underway to assess safety, tolerability and preliminary efficacy in these high-need segments. The company collaborates with leading orthopedic surgeons and academic centers to design protocols and gather real-world insights that may inform future pivotal trials.

Founded in the late 2010s and headquartered in New Jersey, Bone Biologics has assembled a leadership team with extensive experience in regenerative medicine, cell therapy manufacturing and orthopedic clinical development. The company maintains partnerships with contract development and manufacturing organizations to scale its cell production processes, while engaging regulatory consultants to support filings with health authorities. As a dedicated cell therapy innovator, Bone Biologics aims to address significant unmet needs in bone repair and establish new standards for patient outcomes in orthopedic care.

View Bone Biologics Profile